Opendata, web and dolomites

IcoCell

Cell line development platform for SMEs to reduce the length and cost of biologic drug development

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IcoCell project word cloud

Explore the words cloud of the IcoCell project. It provides you a very rough idea of what is the project "IcoCell" about.

expensive    recombination    standard    player    documentation    2014    gt    amplification    2021    reduces    factories    generating    robotic    landing    compatible    advantages    facilities    expression    indications    integration    smes    screening    groups    months    insertion    faster    platform    outcomes    12    implementing    time    lower    drugs    optimizing    line    fewer    200    revenues    lines    creative    yield    26m    900    sensitive    efficient    industry    20x    therapeutic    tools    icf    exceeds    flexible    cell    160    initial    rational       grow    biologic    breakthrough    dependent    of    units    types    preparing    biotech    penetrate    industrial    proteins    health    billion    demonstrating    commercialization    regulatory    platforms    investment    icocell    limiting    throughput    capital    900m    healthcare    2022    biotechnology    develops    stem    protein    predefined    lack    cagr    mean    sites    market    therapies    burdening    mammalian   

Project "IcoCell" data sheet

The following table provides information about the project.

Coordinator
ICOSAGEN CELL FACTORY OU 

Organization address
address: EERIKA TEE 1
city: KAMBJA VALD
postcode: 61713
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Estonia [EE]
 Project website https://icosagen.com/icocell
 Total cost 1˙614˙000 €
 EC max contribution 1˙129˙800 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-2-2015
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ICOSAGEN CELL FACTORY OU EE (KAMBJA VALD) coordinator 1˙129˙800.00

Map

 Project objective

Biologic drugs ($160 billion market) provide better long-term health outcomes with fewer side effects than many traditional drugs. However, due to high development and production costs, these drugs are 20x more expensive, on average, limiting the access to these therapies and burdening healthcare systems. To a great extent, this is because traditionally flexible and creative biotech SMEs currently lack rational tools for mammalian cell line development (most of the biologic drugs are produced in mammalian cell lines), meaning that large investment in terms of capital and time is required to make a production cell line.

ICF, an established player in the biotechnology industry, develops a technology for more efficient development of mammalian cell lines for high-yield protein production. It reduces the need for robotic systems and high-throughput screening facilities (€900 000 -> €200 000), the time (6-12 months -> 3) and cost (€100 000 -> €50 000) of cell line development. These advantages stem from specific landing platforms, predefined integration sites, recombination-dependent insertion and amplification of expression units. The technology will enable biotech SMEs to develop the process of production of new biologic drugs at lower costs and faster, eventually enabling biologic drugs to penetrate more cost-sensitive indications and target groups.

IcoCell project is aimed at optimizing the landing platform, generating cell lines compatible with process of development of industrial cell factories, generating regulatory documentation, preparing standard operating procedures, demonstrating the production of different types of proteins and implementing initial exploitation activities.

Cell line development market is expected to grow at CAGR of 12.8% (2014-2022) and the market for cell line development to produce therapeutic proteins exceeds €900M. Commercialization of IcoCell technology will mean breakthrough for ICF, increasing revenues by an estimated €26M in 2021

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ICOCELL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ICOCELL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More  

SINUSLIGHT (2018)

Laser-spectroscopic sensing device for diagnostic assessment of sinusitis

Read More